With the earlier definition of chronic obstructive pulmonary disease (COPD), patients were essentially defined as having either chronic bronchitis or emphysema, with emphysema classified as a ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

It was a landmark year for medical advancements in 2024, bringing a wave of innovative treatments that promise to reshape ...

In most cases, leftover pathology samples are thrown away. Sometimes though, they may be used again for other purposes, ...

P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the ...

Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced positive topline results from two ...

John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile.

Belarusian cardiologists work real miracles. What transformations in the medical sector does government support prompt?About fifty ...

Young teens might think smoking makes them look cool, but it’s likely to take their breath away in adulthood, a new st ...